Poly-ADP-ribose Polymerase Inhibitor Use in Ovarian Cancer: Expanding Indications and Novel Combination Strategies

The use of poly(ADP-ribose) polymerase inhibition (PARPi) is transforming the current standard of care for the treatment of ovarian cancer, with three different PARP inhibitors gaining U.S Food and Drug Administration (FDA) approval since 2014. Given the rapidly expanding use of PARP inhibitors, thi...

Full description

Saved in:
Bibliographic Details
Published in:Int J Gynecol Cancer
Main Authors: Hinchcliff, Emily M., Westin, Shannon N., Dal Molin, Graziela Z., LaFargue, Christopher, Coleman, Robert L.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8263126/
https://ncbi.nlm.nih.gov/pubmed/31118216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ijgc-2019-000499
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items